Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Jessica Morris

PATIENT’S AND DOCTORS JOINT STORY: Doctor and Patient working together to form OurBrainBank

FleishmanHillard, USA

Anna Danilewicz

JOINT PRESENTATION: Vendor selection for sponsors – how to utilise the Request for Proposal (RFP) data to achieve the best partner

Avillion, UK

Vanessa Dos Reis Ferreira

CASE STUDY: The journey of Santhera Pharmaceuticals to effectively engage with patient groups in clinical trials

Santhera, Switzerland

Dr. Hilde Vanaken

CASE STUDY: First of Its Kind Smart Trial and Engagement Program Implemented on a phase II clinical trial with Alzheimer Patients

Janssen, Pharmaceutical Companies of Johnson & Johnson, Belgium

Richard FitzGerald

CASE STUDY: What it’s like to be an Investigator on a trial?

Royal Liverpool University Hospital, UK

Edouard Masurel

CASE STUDY: Managing Outsourcing Risk: The global and regional picture

GlaxoSmithKline, UK

Jill Gallagher

CASE STUDY: Critical Path for Parkinson’s: Improving clinical trials to deliver better treatments

Parkinson's UK

Morten Thorup Pedersen

CASE STUDY: Quality Tolerance Limits – implementation in a large pharmaceutical company

NovoNordisk, Denmark

Richard FitzGerald

The NCRI Consumer Forum - How patient partners can help Investigators and Industry

Royal Liverpool University Hospital, UK

Mark Pollock

Innovation and Technology -Exploring possibilities where humans and technology collide

Collaboration Catalyst, Ireland

Nov 28
Show Filter
07:30 - 08:50

Registration and morning coffee

Showing of Streams
10:40 - 11:25

Morning coffee and networking

11:25 - 11:30
Opening remarks from the chairperson

Opening remarks from the chairperson

Showing of Streams
13:00 - 14:30

Lunch

Lunchtime activities

  • Exhibition hall viewing




more
Showing of Streams
15:30 - 16:00

Afternoon Break

Showing of Streams
Showing of Streams
18:30 - 19:30

Drinks Reception

19:30 - 19:35
End of Drinks Reception

End of Drinks Reception

07:30 - 08:50 80 mins
Registration and morning coffee
08:50 - 09:00 10 mins
OPENING PLENARY
Opening remarks from the chairperson
09:00 - 09:40 40 mins
OPENING PLENARY
PATIENT’S AND DOCTORS JOINT STORY: Doctor and Patient working together to form OurBrainBank
  • Jessica Morris - Co-founder, OurBrainBank, SVP and Partner, FleishmanHillard, USA
  • Dr. Alexis Demopoulos - Neurology, Medical Oncology, New York Hospital, USA
more
09:40 - 10:40 60 mins
OPENING PLENARY
PANEL: How to manage different goals of sponsor, CRO, Patients, Regulators and Investigators
  • Moderator Dr. David Bull - English Doctor, Television Host, Entrepreneur, David Bull, UK
  • Alison Holland - Vice President & General Manager, Inflammation, Infectious Diseases, and General Medicine, Covance, UK
  • David Swanger - Vice President of Product Marketing, Medidata, USA
more
  • Optimizing the future of clinical trials
  • How can we achieve this goal for everyone?
  • Representing the patient in study design, planning and conduct
  • What are the tensions?
  • How to overcome the challenges?
10:40 - 11:25 45 mins
Morning coffee and networking
11:25 - 11:30 5 mins
Opening remarks from the chairperson
11:30 - 12:00 30 mins
STREAM 1: Partnerships and Collaboration
JOINT PRESENTATION: Vendor selection for sponsors – how to utilise the Request for Proposal (RFP) data to achieve the best partner
  • Anna Danilewicz - Director of Clinical Development, Avillion, UK
  • Kieran Canisius - Managing Partner, Suess Consult, The Netherlands
more
11:30 - 12:00 30 mins
STREAM 2: Patients as Partners
PATIENTS STORY: 'Partners in research': Why patients should be part of the entire research process from bench to clinic - Insights from my personal journey through Parkinson’s research
  • Benjamin Stecher - Education Consultant, Writer and and Parkinson's Disease Patient Advocate, Parkinson’s Research Advocacy Group, Canada
more
  • The pace of novel advances seems to be slowed down by a system that cannot move fast enough to keep up with our own neurodegeneration
  • The “average PD patient” is a statistical construct rather than a physical entity
  • Too often, these clinical trials seem to be conducted to support new patents rather than patients
  • As a first step towards ameliorating these problems, patients should become part of the clinical trial design process. Rather than just being told which hoops to jump through they should be recognized as partners in research
  • We need patient-scientist teams to work together to maximize the likelihood that studies are designed in a way that will ultimately best inform patient and clinician treatment decisions
11:30 - 12:00 30 mins
STREAM 3: Mobile Health and Wearables
CASE STUDIES: "Ready Participant One": The patient-centric Clinical Trial of the future
  • Bruce Hellman - CEO, uMotif, UK
more
  • Informed consent: Patients need to know what’s expected
  • Data ownership: Trust and balance across all partners
  • Data capture: Combination of a range of sources
  • And this future is now - case studies from across the industry
11:30 - 12:00 30 mins
STREAM 4: Governance, Quality, Oversight and Risk Management
CASE STUDY: How Novartis governs risk Management in clinical trials
  • Ms Isabelle Naeije - Clinical Trial Head, GDO Trial Management Oncology, Novartis Pharma AG, Switzerland
more
  • What are the recommendations from the regulators?
  • What can we put in place in our trials?
  • Which monitoring model for the future?
11:30 - 12:00 30 mins
STREAM 5: Investigator & Industry Partnership
CASE STUDY: Best Practices for Site Identification and Selection
  • Christian Milliet - Global Head Clinical Operations, Vifor Pharma, Switzerland
more
  • Major challenges in a competitive landscape
  • Available tools and sources for site identification
  • The Feasibility Study 2.0
  • Benefits of direct site contact
12:00 - 12:30 30 mins
STREAM 1: Partnerships and Collaboration
Partnership for access to medicine in neglected populations
  • Michael Mihut - Portfolio Management Officer, The Special Programme for Research and Training in Tropical Diseases, World Health Organization, Switzerland
more
12:00 - 12:30 30 mins
STREAM 2: Patients as Partners
CASE STUDY: The journey of Santhera Pharmaceuticals to effectively engage with patient groups in clinical trials
  • Vanessa Dos Reis Ferreira - Head of Patient Advocacy Europe, Santhera, Switzerland
more
  • Preparation for and encouragement of feedback from patient groups
  • Challenges, obstacles and getting through them
  • Impact on company decisions after patient groups feedback
  • Recommendations
12:00 - 12:30 30 mins
STREAM 3: Mobile Health and Wearables
CASE STUDY: First of Its Kind Smart Trial and Engagement Program Implemented on a phase II clinical trial with Alzheimer Patients
  • Dr. Hilde Vanaken - Clinical Innovation Director, Janssen, Pharmaceutical Companies of Johnson & Johnson, Belgium
more
  • Impact of personalized patient engagement and automated real-time data collection on patients, sites and company via smart phones, smart blisters and scanning devices
  • Ensuring the “right” kit and “right” pill is given to the “right” patient at all times
  • Improving patient’s understanding of drug information and all-in-one digital drug labels.
  • Value of engaging patients, sites, health authorities and ethics committees directly during the development of smart technologies
  • Transforming clinical trials by disruptive partnerships with technology, software, mobile and package vendors.
12:00 - 12:30 30 mins
STREAM 4: Governance, Quality, Oversight and Risk Management
CASE STUDY: Operational risk management- A systematic approach to identifying risk in clinical trials upfront
  • Diana Sims-Silbermann - Senior Trial Manager, Early Development and Clinical Pharmacology,, Janssen-Cilag GmbH, Johnson & Johnson, Germany
more

Protocol risks:

  • Complicated IP preparation
  • IP with potential side effects (e.g. biologicals)
  • Extensive PK days
  • Complicated Trial specific activities
  • Timelines on processes that affect trial conduct (e.g.long TAT for certain lab assessments, timelines for entering data into IWRS to receive medication)
  • Site risks:
  • Adequate site staff
  • Adequate site staff experience
  • PI oversight
  • Adequate equipment
  • What can sponsor /CRA do?
  • risk mamangement assessment of protocol taking site capabilities into account before trial starts
  • identify and mitigate possible “danger points” upfront
  • discuss these points with site staff at SIV
  • During trial
  • close contact with sites to  monitor identified risks in real time

   

12:00 - 12:30 30 mins
STREAM 5: Investigator & Industry Partnership
CASE STUDY: Engagement with sites
  • Ms Jeannett Dimsits - Senior Director, Trial Management Anchor, NovoNordisk, Denmark
more
12:30 - 13:00 30 mins
STREAM 1: Partnerships and Collaboration
Sponsored Speaking Slot - PRA
more
12:30 - 13:00 30 mins
STREAM 2: Patients as Partners
Sponsored Speaking Slot - ERT
more
12:30 - 12:40 10 mins
STREAM 3: Mobile Health and Wearables
Innovation Den
12:30 - 13:00 30 mins
STREAM 4: Governance, Quality, Oversight and Risk Management
Sponsored Speaking Slot to Fill
more
12:30 - 13:00 30 mins
STREAM 5: Investigator & Industry Partnership
JOINT PRESENTATION: Clinical Trial Payment Software and success factors, lessons learned and results
  • Joe Robbins - Senior Manager, Global Clinical Pricing & Payments, Amgen, UK
  • Jim Murphy - CEO, Greenphire
more

Attend this joint presentation to learn how Amgen chose Greenphire’s eClinicalGPS to automate its site payments for a more transparent, reliable process that eliminated as many manual points of intervention as possible.

  • How the holistic approach included standardization of global budget processes, creating an internal clinical payments database and implementing key integrations (ERP, EDC) to distribute payments to sites
  • Automating configuration improves controls, reduces errors and keeps the sponsor in the ownership role
  • Site payment automation allows the sponsor to eliminate holdback, pay more frequently, accurately with full transparency
  • Key findings from the pilot program, global implementation and worldwide payment transformation
12:40 - 12:50 10 mins
STREAM 3: Mobile Health and Wearables
Innovation Den
12:50 - 13:00 10 mins
STREAM 3: Mobile Health and Wearables
Innovation Den
13:00 - 14:30 90 mins
Lunch
more

Lunchtime activities

  • Exhibition hall viewing




14:30 - 15:00 30 mins
STREAM 1: Partnerships and Collaboration
CASE STUDY: Out-Tasking
  • Lourdes López-Bravo - Executive Director, Clinical Research Director Spain and Portugal, Global Clinical Trial Operations,, MSD, Spain
more
14:30 - 15:00 30 mins
STREAM 2: Patients as Partners
CASE STUDY: A rare disease in clinical trial: The Duchenne parent project Spain strategy
  • Marisol Montolio del Olmo - Adjunct Professor at University of Barcelona and Scientific Director, of Duchenne Parent Project Spain, Spain
more
  • Clinical Trial Support: Save drugs from Valley of death
  • Patients' Registry
  • Collaboration with Pharma
  • Input to EMA
  • Inform to Patients
14:30 - 15:00 30 mins
STREAM 3: Mobile Health and Wearables
CASE STUDY: Childhood Cancer Survivorship Passport: An integrated eHealth solution
  • Ruth Ladenstein - Senior Consultant in Paediatric haematology–Oncology, OKIDS, Austria
more
  • Continuity of Care and Advise
  • Survivorship Passport
  • Interoperable electronic Health Records
  • Patient Empowerment
  • Long Term Follow Up Research
14:30 - 15:00 30 mins
STREAM 4: Governance, Quality, Oversight and Risk Management
CASE STUDY: RBM -key conditions in collaboration between Sponsor and CRO
  • Marion Wolfs - Deputy Head| Director Risk Management and Central Monitoring, TA lead oncology heme and ED/CP, Janssen, Pharmaceutical Companies of Johnson & Johnson, Belgium
more

Although Risk Based Monitoring (RBM) high level definitions and processes are similar across the pharmaceutical industry, the practical implementation, organizational structures, naming of documents and processes, system capabilities, etc., can be different from company to company. Through an Alliance Level Relationship with our preferred CROs, we have gained experience and developed best practices with RBM operational deployment, particularly regarding RBM set-up and collaboration between Sponsor and CRO. Clarity around roles and responsibilities as well as a good understanding of system capabilities and data flows, especially where there are shared systems between the Sponsor and CRO, are found to be key success factors. Besides possible organizational changes and the development of mutual processes and system capabilities, the human element is not to be underestimated. Managing the changes in processes and change in mind set within both the Sponsor and CRO organization is crucial to successful implementation of RBM.

14:30 - 15:00 30 mins
STREAM 5: Investigator & Industry Partnership
CASE STUDY: What it’s like to be an Investigator on a trial?
  • Richard FitzGerald - Consultant Physician and Director, Clinical Research Unit, Royal Liverpool University Hospital, UK
more
15:00 - 15:30 30 mins
STREAM 1: Partnerships and Collaboration
Sponsored Speaking Slot - Bioclinica
more
15:00 - 15:30 30 mins
STREAM 2: Patients as Partners
Making it easier for patients to learn about and participate in clinical trials: A practical approach to patient centricity
  • Rosamund Round - Associte Director Patient Recruitment, PAREXEL, UK
more
  • Benefits of the patient centricity phenomenon
  • Addressing literacy and health literacy to enhance clinical trial understanding
  • How to incorporate the patient perspective into the protocol design process
  • What can be done to reduce financial, geographical and practical challenges to trial participation
  • Through case studies and examples, understand the practical application of a patient centric approach to planning and implementing clinical trials
15:00 - 15:30 30 mins
STREAM 3: Mobile Health and Wearables
CASE STUDY: Use of technology to access isolated populations to improve lifelong health and education
  • Véronique Inés Thouvenot - Co-Founder CCO, & Scientific Director, Millennia2025 Women and Innovation Foundation, Switzerland
more
  • How isolated populations have access and use technologies for their health and education – case studies in Peru, Brazil, Nigeria, Nepal and Mongolia.
  • How technologies are used from birth to elderly
  • How local knowledge is collected and shared with technologies
  • What challenges have still to be overcome to enhance security in the communities
  • What can we learn from these examples to benefit clinical trial design and the promotion of long-term healthcare solutions
15:00 - 15:30 30 mins
STREAM 4: Governance, Quality, Oversight and Risk Management
CASE STUDY: Managing Outsourcing Risk: The global and regional picture
  • Edouard Masurel - Head of Third Party Resourcing (TPR) - Regions and LOCs, GlaxoSmithKline, UK
more
  • How can we better mitigate, control or reduce risk associated with outsourcing?
  • What are the industry trends and best practices?
  • How to do it? Getting control of all outsourcing that is happening in the regions
  • How to achieve smarter resourcing in a global context
15:00 - 15:30 30 mins
STREAM 5: Investigator & Industry Partnership
Sponsored Speaking Slot to Fill
15:30 - 16:00 30 mins
Afternoon Break
16:00 - 16:30 30 mins
STREAM 1: Partnerships and Collaboration
CASE STUDY: Critical Path for Parkinson’s: Improving clinical trials to deliver better treatments
  • Jill Gallagher - Clinical Development and Regulatory Manager, Parkinson's UK
more
  • This is a global collaboration that promises to pave the path to new treatments for Parkinson’s.
  • Collaboration among scientists from the bio-pharmaceutical industry, academic institutions, government agencies, and patient-advocacy associations,
  • CPP fosters data-driven research to increase efficiency, safety, and speed in developing new therapies.
  • CPP is the main international vehicle to develop new, regulatory-endorsed drug development tools
  • Update on progress so far in achieving regulatory endorsement of biomarkers,
  • Plans for development of a clinical trial simulation platform and information about how to become part of this exciting collaboration.
16:00 - 16:30 30 mins
STREAM 2: Patients as Partners
Delivering meaningful patient centricity in clinical trials: The patient organisation perspective
  • Panellist Chris Macdonald - Research Involvement Manager, Arthritis Research UK
more
  • Hear how UK medical research charities have been successfully integrating patient insight in to their activities for over 10 years
  • Find out how they strike a practical balance of delivering effective research outcomes whilst ensuring relevance through principled and meaningful patient involvement
  • Through case studies and examples, explore how industry and medical research charities can learn from one another and collaborate for mutual benefit in clinical trials
  • Discuss the body of evidence and moral imperative that is quickly making patient centricity a key focus of those delivering clinical trials and regulators
16:00 - 16:30 30 mins
STREAM 3: Mobile Health and Wearables
CASE STUDY: Use of technology in clinical trials
  • Judith Kornfield - Chief Business and Operations Officer, Oregon Health & Sciences University, USA
more
16:00 - 16:30 30 mins
STREAM 4: Governance, Quality, Oversight and Risk Management
CASE STUDY: Quality Tolerance Limits – implementation in a large pharmaceutical company
  • Morten Thorup Pedersen - Risk Based Monitoring Specialist, NovoNordisk, Denmark
more
  • Introduction to Quality Tolerance Limits (QTLs)
  • What does ICH-GCP require the industry to do
  • What is TransCelerate’s approach to QTLs
  • How to establish a framework for implementing QTLs
  • How to define QTLs and for which parameters
  • How to monitor QTLs
16:00 - 16:30 30 mins
STREAM 5: Investigator & Industry Partnership
The NCRI Consumer Forum - How patient partners can help Investigators and Industry
  • Richard FitzGerald - Consultant Physician and Director, Clinical Research Unit, Royal Liverpool University Hospital, UK
more
16:30 - 17:30 60 mins
STREAM 1: Partnerships and Collaboration
PANEL: The evolution of outsourcing strategies: Managing change through M&A in stakeholders during outsourcing and strategic partnerships
  • Varun Grover - Clinical Contracts and Finance, Senior Associate, Gilead Sciences, UK
  • Lan Bandara - Global Head of Outsourcing, Eisai Limited, UK
  • Ms Lidia Cappellina - Head of Outsourcing Management, Chiesi, Italy
  • Dr Stephen Walker - Outsourcing Programme Director, AstraZeneca, UK
more
  • Impact of mergers and acquisition of the CRO’s on the Pharma Industry, risks and opportunities from M&A, a sponsor’s perspective? CROs should maintain a high level of performance, CRO staff turnover as result of M&A?
  • Mergers and Acquisition of CRO- how do you still take forward the partnership? How does this impact the trial? How to keep fresh and on-track when this happens? How well is the integration managed? Business continuity and risk management during M&A period
  • Real-life experience of what can go wrong in a partnership and how can this be avoided? CROs to be aware of the new sponsors culture, how to remain versatile, preferred provider for Sponsor?
  • Quality oversight during a fully outsourced study, including pitfalls and solutions
  • Is this the death of small specialist CROs?
  • How to manage change after M&A, the impact on contracts and budgets with CRO/Sponsors, exploring other types of contracting models best suited to adapt to change, what constitutes a change in scope?
  • Monitoring supplier performance, introducing KPI’s
16:30 - 17:30 60 mins
STREAM 2: Patients as Partners
PANEL: Patient Engagement – discussing the value and has it actually made a difference to the Pharmaceutical companies?
  • Vanessa Dos Reis Ferreira - Head of Patient Advocacy Europe, Santhera, Switzerland
  • Jennifer Preston - Patient and Public Involvement & Engagement Priority Lead, Dept. of Women's and Children's Health, Alder Hey Children's NHS Foundation Trust University of Liverpool, UK
  • Dr Vanessa Spalding - Clinical Project Management Advisor, Neuroscience, Clinical Pharmacology, Eli Lilly and Company Limited, UK
  • Russell Wheeler - Trustee, Leber's Hereditary Optic Neuropathy Society (LHON Society), UK
  • E.B. McLindon - Senior Vice President, Site & Patient Recruitment, ICON plc
more
  • Has the focus on Patient Centricity really speeded up the development of molecules?
  • What costs implications are there being patient centric?
  • Is it really changing protocols? Is it delaying start-up times?
  • Have they recruited faster? Is it actually delivering on recruitment better retention?
  • Compare recruitment and retention from a study 5 years ago to now- do we see a difference?
  • What are companies doing? What’s the value in it
  • Involving patients from start to finish - Engage for protocol development  through to end
  • Engaging patients to talk to regulators?
  • Have they got better data? Have they got faster approval? What is the feedback from regulators?
  • Holistic made people feel good, helping with pharma industry profile
  • Has it had a positive feedback?
  • What are the Regulators viewpoint on this? Engaging with patients- how will they respond to that? FDA has done patient engagement… how do they view patient engagement? Study design or end points have bene requested by patients? How do they react to that?
  • Experience of patients may be better but is it speeding up clinical research?
  • Multiple different consortia: Transcelerate, EFPIA , IMI (International Medicine? industry funded)
16:30 - 17:30 60 mins
STREAM 3: Mobile Health and Wearables
PANEL: Wearables and sensors - Different ways to collect clinical data- what does it mean for clinical trials?
  • Bert Hartog - Director, R&D Operations Innovation, Janssen Pharmaceutica, Belgium
more
  • Mobile Health - Taking clinical trial to the patient - Shifting clinical research from hospital to home – when will this happen?
  • Choosing the right device for your trial - what are the requirements?
  • What do you do with all the data? How much do you use? How will companies analyse that data? How will agencies accept the data?
  • How to look at it in a risk based manner?
  • what to think about when validate the devices, what can you use them
  • Can you ignore a large proportion of this data or do you have a responsibility to look at it?
  • What extent are people, using them? What results have been submitted?
  • Experiences – who has done it? What did they found out? What are the difficulties?
  • What evidence is there with regulated trials?
  • MHealth market will explode- right economic model? How money will be generated?
  • How do you generate more value for your clinical programme by using wearables? How to translate into the real world?
  • Validity of the payers and the validity of data regulators acceptance of data
  • Ethical issues- are devices just given out and then taken away? Do people, keep the device
  • Can I trust the technology?
  • MHealth gives you visibility and insight into what patients are genuinely doing
  • Making trials accessible for many more people – allow people to participate who can’t get to hospitals
  • Suppliers who cannot offer global services for technology, helpdesk, handling data with different trails- the global trials are not possible
  • Make this way of working fit in current healthcare. Do investigators like patients staying at home.
16:30 - 17:30 60 mins
STREAM 4: Governance, Quality, Oversight and Risk Management
PANEL: Optimising the Sponsor-CRO partnership: Quality oversight in outsourced clinical trials
  • Geoff Taylor - Director, Clinical Quality Assurance,, Eisai Product Creation Systems, UK
  • Dr Raphaele Mary - former Director Capability & Strategy, Global Clinical Operations, Bristol Myers Squibb
  • Marion Wolfs - Deputy Head| Director Risk Management and Central Monitoring, TA lead oncology heme and ED/CP, Janssen, Pharmaceutical Companies of Johnson & Johnson, Belgium
more
  • Balance between micromanagement and oversight
  • Developing and implementing the right tools for sponsor and CRO quality oversight
  • How much oversight is overkill?
  • The role of quality management agreements: How to set the right foundation for the quality management relationship
  • Guidelines for ongoing evaluation of the quality management partnerships between CROs and Sponsors
16:30 - 17:30 60 mins
STREAM 5: Investigator & Industry Partnership
PANEL DISCUSSION: Site budget in Clinical Trials – What is “fair market value?
  • Diana Sims-Silbermann - Senior Trial Manager, Early Development and Clinical Pharmacology,, Janssen-Cilag GmbH, Johnson & Johnson, Germany
  • Philipp Badorrek - Head of Department,, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Germany
  • Wolfgang Seibold - Clinical Operations, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
  • Dmitry Manuilov - Head of Clinical Development, MYR GmbH, Germany
more
  • Offered budget for set up is often far too low, especially in multi-centre trials. (ever increasing training requirements and document  reviews (lab manual, procedure manual, protocol, CRF)
  • Why is there so often a marked difference in budgets between early phase and late phase trials? The need for training and the level of quality is the same!!
  •  Activities outside the mere procedure costs are often not recognised, like time to enter CRFs, communication time with sponsor/CRO, internal team meetings, etc.
17:30 - 17:35 5 mins
CLOSING PLENARY
Opening remarks from the Chairperson
17:35 - 17:40 5 mins
CLOSING PLENARY
Lifetime achievement award
17:40 - 18:30 50 mins
CLOSING PLENARY
Innovation and Technology -Exploring possibilities where humans and technology collide
  • Mark Pollock - Explorer, Innovator &, Collaboration Catalyst, Ireland
more
  • Adversity and challenges - Resilience and attitude under pressure
  • Leadership and motivation - Goal setting and leading through a crisis
  • Collaboration and teamwork - Creating and motivating dispersed teams across disciplines and geographies
18:30 - 19:30 60 mins
Drinks Reception
19:30 - 19:35 5 mins
End of Drinks Reception